Q-omics provides the consensus-scored NKX2-1 profile across patient tissues and cancer cell-line models. NKX2-1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NKX2-1 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, NKX2-1 protein abundance shows 18,508 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, LUSC, and LSCC as cancer lineages where NKX2-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NKX2-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NKX2-1 survival associations across molecular data types. NKX2-1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NKX2-1 RNA expression–survival associations across cancer types. High NKX2-1 expression shows unfavorable associations in HNSC, LUSC, KIRC, MESO and ACC, but favorable associations in LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for NKX2-1 RNA expression.
This table summarizes NKX2-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 4. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NKX2-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NKX2-1 shows lower tumor expression in LUSC and LUAD and higher tumor expression in BLCA, HNSC, PRAD and THCA. The LUSC box plot shows higher NKX2-1 RNA expression in normal versus tumor tissue (log2 FC = −4.611, t-test p < 0.001).
This table shows molecular features associated with NKX2-1 in patient tissues and cancer cell lines. In patient samples, NKX2-1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NKX2-1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_SCLC.
